Search results
Results from the WOW.Com Content Network
Cardiotoxicity is a major problem with people treated with higher dose regimens. [23] High-dose intravenous cyclophosphamide can cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a potentially fatal hyponatremia when compounded by intravenous fluids administered to prevent drug-induced cystitis. [24]
3 Side-effects and complications. 4 ... (cyclophosphamide, Oncovin, and prednisone or ... some researchers tried to escalate chemotherapy to very high doses ...
Mesna, sold under the brand name Mesnex among others, is a medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder. [1] It is used either by mouth or injection into a vein. [1] Common side effects include headache, vomiting, sleepiness, loss of appetite, cough, rash, and joint pain. [1]
High-dose chemotherapy (HDC) is a regimen of chemotherapy medicines given at larger dosages. This therapeutic strategy is used to treat some cancers, especially those that are aggressive or have a high chance of coming back. With increased doses of chemotherapy chemicals administered to the body, HDC seeks to optimize the death of cancer cells.
The term 'hyper' refers to the hyperfractionated nature of the chemotherapy, which is given in smaller doses, more frequently, to minimize side effects. 'CVAD' is the acronym of the drugs used in course A: cyclophosphamide, vincristine, doxorubicin (also known by its trade name, Adriamycin), and dexamethasone.
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
"While it’s true it's difficult to meet the RDA daily dose of 75 to 90 milligrams of vitamin C by eating only meat, there are about 25 micrograms per gram of vitamin C in fresh, grass-fed beef ...
Ninety patients were randomised to compare two cycles of high-dose cyclophosphamide, mitoxantrone, and etoposide (HD-CNV) versus six to eight cycles of conventional-dose cyclophosphamide, mitoxantrone, and vincristine (CNV). The overall response rate for HD-CNV was 95%, with 23 of 45 patients achieving complete response (remission).